ORTX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Jan 2024 @ 22:00):

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...

Stats
Tagesvolumen	372 349
Durchschnittsvolumen	105 224
Marktkapitalisierung	380.11M
EPS	$0 ( 2024-03-04 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.07
ATR14	$0.0590 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Secor Alicia	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Secor Alicia	Sell	105 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	44 391	Ordinary Shares
2024-01-24	Geraghty James A	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	105 000	Stock Option (Right to Buy)

INSIDER POWER
-31.75
Last 99 transactions
Buy: 13 341 271 \| Sell: 6 351 136

Volumen Korrelation

Lang: 0.03 (neutral)

Kurz: 0.00 (neutral)

Signal:(85.364) Neutral

Orchard Therapeutics PLC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Orchard Therapeutics PLC Korrelation - Währung/Rohstoff

-0.79
( moderate negative )

-0.70
( moderate negative )

0.11
( neutral )

-0.74
( moderate negative )

-0.01
( neutral )

0.59
( weak )

Orchard Therapeutics PLC Finanzdaten

Annual	2022
Umsatz:	$6.99M
Bruttogewinn:	$4.55M (65.17 %)
EPS:	$-0.610

FY	2022
Umsatz:	$6.99M
Bruttogewinn:	$4.55M (65.17 %)
EPS:	$-0.610

FY	2021
Umsatz:	$1.68M
Bruttogewinn:	$1.45M (86.51 %)
EPS:	$-1.170

FY	2020
Umsatz:	$2.60M
Bruttogewinn:	$1.74M (66.97 %)
EPS:	$-1.530

Financial Reports:

No articles found.

Orchard Therapeutics PLC

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.